Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Assess Safety and Efficacy of ANG- 3777 in Patients Hospitalized With Confirmed COVID-19 Pneumonia

Next Previous
Trial Profile

A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Assess Safety and Efficacy of ANG- 3777 in Patients Hospitalized With Confirmed COVID-19 Pneumonia

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Jun 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Terevalefim (Primary)
  • Indications Acute lung injury; COVID 2019 infections; COVID-19 pneumonia
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Angion Biomedica; Elicio Therapeutics

Most Recent Events

  • 01 Jun 2023 According to an Elicio Therapeutics media release, Angion Biomedica merged with the Elicio Therapeutics and the combined company is called as Elicio Therapeutics.
  • 29 Jun 2021 According to an Angion Biomedica media release, Primary endpoint (Proportion of patients alive, without the need for mechanical ventilation and free of the need for RRT (on an ongoing basis) at Day 28) has not been met.
  • 29 Jun 2021 Results presented in an Angion Biomedica Media Release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top